SCHEMBL5136841

SCHEMBL5136841

CCCCn1c(-c2ccccc2)nc(-c2ccc(OC)cc2)c1CN(Cc1ccccc1)Cc1ccc(O)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.39
ALDH1A1 P00352 4/20 0.37
MAPT P10636 3/20 0.37
NPSR1 Q6W5P4 2/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GAA P10253 3/20 0.37
TSPO P30536 3/20 0.36
PDK1 Q15118 1/20 0.36
KDM4E B2RXH2 3/20 0.36
TSHR P16473 2/20 0.36
LMNA P02545 2/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
BCHE P06276 3/20 0.35
TLR7 Q9NYK1 1/20 0.34
HSD17B10 Q99714 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4764487 0.93 C5AR1 (0.43) C5AR1ALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL4766462 0.93 TLR7 (0.41) C5AR1MAPTSMN1; SMN2GAAPDK1
SCHEMBL5136819 0.93 TSPO (0.40) C5AR1ALDH1A1MAPTNPSR1GAA
SCHEMBL5136126 0.90 C5AR1 (0.40) C5AR1PDK1TSHR
SCHEMBL5073890 0.89 C5AR1 (0.42) C5AR1ALDH1A1MAPTNPSR1TP53
SCHEMBL5138072 0.89 C5AR1 (0.43) C5AR1ALDH1A1HPGDSMN1; SMN2GAA
SCHEMBL5136565 0.88 BCL2L2 (0.36) C5AR1ALDH1A1HPGDPDK1KDM4E
SCHEMBL5136545 0.88 C5AR1 (0.43) C5AR1ALDH1A1MAPTNPSR1TP53
SCHEMBL5136216 0.86 C5AR1 (0.41) C5AR1
SCHEMBL5137492 0.86 C5AR1 (0.42) C5AR1ALDH1A1HPGDSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed